This inventor holds 37 USPTO granted patents and 2 published patent applications and 3 EPO patents, primarily in PARP Inhibitors. Top assignees: Guilford Pharmaceuticals, Inc., Eisai Inc., Mgi Gp, Inc.. Active years: 2000-2014.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Ellicott, MD (US) (2001)
- Ellicott City, MD (US) (2000 - 2014)
- Baltimore, MD (US) (2007 - 2014)
- Ellicot City, MD (US) (2007 - 2014)
Company Filing History:
21 out of 98 
9 out of 33 
5 out of 7 Years Active: 2000-2014
Areas of Expertise:
Title: Innovations by Jie Zhang: Pioneering PARP Inhibitor Compounds
Introduction
Jie Zhang, based in Ellicott City, MD, is a remarkable inventor who has made significant contributions to the field of cancer therapeutics. With an impressive portfolio of 37 patents, Zhang focuses on innovative compounds and methods aimed at enhancing cancer treatment efficacy.
Latest Patents
Among Jie Zhang's latest innovations are two notable patents that revolve around PARP inhibitor compounds. The first patent, titled "PARP inhibitor compounds, compositions and methods of use," introduces tetraaza phenalen-3-one compounds that effectively inhibit poly(ADP-ribose) polymerase (PARP). These compounds are designed to address a critical issue in cancer treatment, which is the unwanted induction of peripheral neuropathy from various chemotherapeutic agents. This patent also discusses using these innovative compounds to enhance the effectiveness of chemotherapeutics like temozolomide and radiosensitize tumor cells to ionizing radiation.
The second patent, "Diazabenzo[de]anthracen-3-one compounds and methods for inhibiting PARP," presents diazabenzo[de]anthracen-3-one compounds with similar mechanisms for inhibiting PARP. This invention focuses on treatment, prevention, and amelioration of the effects of conditions linked to cancer therapies, marking a substantial advancement in the field.
Career Highlights
Jie Zhang's professional journey includes significant roles at renowned companies, including Guilford Pharmaceuticals, Inc. and Eisai Inc. His work in these organizations has been instrumental in the development of innovative solutions in the pharmaceutical industry.
Collaborations
Throughout his career, Zhang has collaborated with distinguished colleagues, such as Jia-He Li and Weizheng Xu. These partnerships have facilitated groundbreaking research and advancements in cancer therapy, highlighting the collaborative nature of scientific innovation.
Conclusion
In summary, Jie Zhang stands out as a leading inventor in the realm of cancer therapeutics, particularly through his development of PARP inhibitor compounds. His ongoing dedication to innovation and research reflects a commitment to improving patient outcomes in oncology, making a lasting impact on the industry and paving the way for future advancements.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile